Company / Operating Cash Flow
Cytokinetics Operating Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$510.0M
FY2025
5-year range
-$510.0M / -$142.5M
FY2021-FY2025
Trend
-28.8%
vs FY2024
Sector context
#209 of 216
Health Care
What the data says
Among 216 Health Care companies, Cytokinetics is in the bottom 3% for operating cash flow. Operating Cash Flow has fluctuated over the past 10 years, ranging from -$510M in FY2025 to $37M in FY2016.
Based on SEC 10-K filings.
-$510M in FY2025.
Declined from -$414M to -$510M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 3% in Health CareTop 97% of 216This company -$510.0M Sector average $658.7M
▼
-177.4% below sector average
Key checks
Key Insights
- In FY2025, operating cash flow decreased 28.8% year-over-year.
- Ranks #209 out of 216 companies in the Health Care sector.
- Peak operating cash flow was recorded in FY2016.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$510.0M | -28.8% |
| FY2024 | -$395.9M | +4.5% |
| FY2023 | -$414.3M | -38.3% |
| FY2022 | -$299.5M | -110.2% |
| FY2021 | -$142.5M | -1693.7% |
| FY2020 | $8.9M | +109.8% |
| FY2019 | -$90.9M | +10.2% |
| FY2018 | -$101.2M | +0.5% |
| FY2017 | -$101.8M | -375.2% |
| FY2016 | $37.0M | +657.4% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026